|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
207,851,000 |
Market
Cap: |
11.72(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$32.18 - $59.82 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
1,788 |
1,788 |
12,464 |
117,983 |
Total Sell Value |
$97,772 |
$97,772 |
$588,604 |
$11,227,385 |
Total People Sold |
2 |
2 |
12 |
18 |
Total Sell Transactions |
2 |
2 |
26 |
70 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Carletti Lorenzo |
SVP Global Ops Ph & Cons Hlth |
|
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
457 |
8,962 |
|
- |
|
Gennadios Aristippos |
Group Pres. Pharma & Consumer |
|
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,590 |
96,948 |
|
- |
|
Lickfold Charles |
SVP, CIO |
|
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
637 |
11,529 |
|
- |
|
Gunther Scott |
SVP, Quality & Reg. Affairs |
|
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,081 |
30,201 |
|
- |
|
Maselli Alessandro |
President & CEO |
|
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
3,974 |
90,075 |
|
- |
|
Grippo Michael J |
SVP, Strategy & Corp. Dev. |
|
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,114 |
24,839 |
|
- |
|
Hopson Ricky |
Pres. Clinical Dev Supply Div |
|
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
789 |
21,836 |
|
- |
|
Pravda Ricardo |
Chief Transformation Officer |
|
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,783 |
29,522 |
|
- |
|
Pravda Ricardo |
Chief Transformation Officer |
|
2023-08-01 |
4 |
S |
$46.50 |
$12,793 |
D/D |
(269) |
19,739 |
|
19% |
|
Hawkeswood Thomas W |
Pres. Pharma Prod Delivery Div |
|
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,306 |
7,412 |
|
- |
|
Hawkeswood Thomas W |
Pres. Pharma Prod Delivery Div |
|
2023-08-01 |
4 |
S |
$47.97 |
$12,376 |
D/D |
(258) |
5,106 |
|
19% |
|
Santiago Karen Murphy |
VP & Chief Accounting Officer |
|
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,342 |
4,763 |
|
- |
|
Arnold Jonathan |
SVP, CCO & Div. Head BioP Del. |
|
2023-08-01 |
4 |
S |
$47.80 |
$2,964 |
D/D |
(62) |
55,896 |
|
19% |
|
Gunther Scott |
SVP, Quality & Reg. Affairs |
|
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,322 |
29,120 |
|
- |
|
Gunther Scott |
SVP, Quality & Reg. Affairs |
|
2023-08-01 |
4 |
S |
$47.90 |
$9,101 |
D/D |
(190) |
23,798 |
|
19% |
|
Gennadios Aristippos |
Group Pres. Pharma & Consumer |
|
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,870 |
95,358 |
|
- |
|
Gennadios Aristippos |
Group Pres. Pharma & Consumer |
|
2023-08-01 |
4 |
S |
$46.58 |
$13,373 |
D/D |
(281) |
86,488 |
|
19% |
|
Lickfold Charles |
SVP, CIO |
|
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,322 |
10,892 |
|
- |
|
Lickfold Charles |
SVP, CIO |
|
2023-08-01 |
4 |
S |
$47.90 |
$6,467 |
D/D |
(135) |
5,570 |
|
19% |
|
Maselli Alessandro |
President & CEO |
|
2023-08-01 |
4 |
S |
$46.71 |
$69,995 |
D/D |
(1,485) |
86,101 |
|
19% |
|
Carletti Lorenzo |
SVP Global Ops Ph & Cons Hlth |
|
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,903 |
8,505 |
|
- |
|
Carletti Lorenzo |
SVP Global Ops Ph & Cons Hlth |
|
2023-08-01 |
4 |
S |
$47.77 |
$18,296 |
D/D |
(383) |
4,602 |
|
19% |
|
Fasman Steven L |
EVP & Chief Admin Officer |
|
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
11,885 |
72,101 |
|
- |
|
Fasman Steven L |
EVP & Chief Admin Officer |
|
2023-08-01 |
4 |
S |
$46.72 |
$77,026 |
D/D |
(1,637) |
60,216 |
|
19% |
|
Grippo Michael J |
SVP, Strategy & Corp. Dev. |
|
2023-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,209 |
23,725 |
|
- |
|
821 Records found
|
|
Page 4 of 33 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|